Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.
Alnylam Pharmaceuticals (NASDAQ: NASDAQ:ALNY) stock climbed 5% as trading resumed on Friday morning, following the company’s announcement that the FDA has approved AMVUTTRA for treating ATTR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback